For acute myeloid leukemia (AML), a possible target is the interleukin 3 receptor alpha (IL-3Rα, also known as CD123), which is overexpressed in AML [summarized in (3)] and expression levels were shown to correlate with clinical prognosis and outcome (4–6). Here, IL3RA is linked to acute myeloid leukemia.